BCYC
Price
$3.48
Change
-$0.24 (-6.45%)
Updated
Nov 5 closing price
Capitalization
243.58M
117 days until earnings call
Intraday BUY SELL Signals
IOVA
Price
$7.74
Change
-$0.96 (-11.03%)
Updated
Nov 5 closing price
Capitalization
3.51B
Earnings call today
Intraday BUY SELL Signals
Interact to see
Advertisement

BCYC vs IOVA

BCYC vs IOVA Comparison Chart in %
View a ticker or compare two or three
VS
BCYC vs. IOVA commentary
Nov 06, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCYC is a Hold and IOVA is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BCYC with price predictions
Nov 04, 2026

Aroon Indicator for BCYC shows an upward move is likely

BCYC's Aroon Indicator triggered a bullish signal on November 04, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 137 similar instances where the Aroon Indicator showed a similar pattern. In 120 of the 137 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BCYC's RSI Oscillator exited the oversold zone, 36 of 48 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on BCYC as a result. In 63 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.

The Moving Average Convergence Divergence (MACD) for BCYC just turned positive on October 22, 2026. Looking at past instances where BCYC's MACD turned positive, the stock continued to rise in 37 of 46 cases over the following month. The odds of a continued upward trend are 80%.

Following a +2.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where BCYC advanced for three days, in 185 of 244 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 47 cases where BCYC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

BCYC moved below its 50-day moving average on October 29, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCYC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

BCYC broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.477) is normal, around the industry mean (2.904). P/E Ratio (-1.275) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (4.136) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. BCYC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCYC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for IOVA with price predictions
Nov 04, 2026

IOVA in -16.11% downward trend, declining for three consecutive days on November 02, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where IOVA declined for three days, in 279 of 320 cases, the price declined further within the following month. The odds of a continued downward trend are 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IOVA as a result. In 72 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for IOVA turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 37 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.

IOVA moved below its 50-day moving average on October 29, 2026 date and that indicates a change from an upward trend to a downward trend.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +7.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where IOVA advanced for three days, in 202 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

IOVA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 141 of 164 cases where IOVA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.850) is normal, around the industry mean (2.904). P/E Ratio (-11.217) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.370) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (12.484) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. IOVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IOVA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
BCYC vs IOVA: Fundamental Ratings
BCYC
IOVA
OUTLOOK RATING
1..100
1055
VALUATION
overvalued / fair valued / undervalued
1..100
33
Fair valued
21
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
6134
P/E GROWTH RATING
1..100
3496
SEASONALITY SCORE
1..100
n/a49

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IOVA's Valuation (21) in the Biotechnology industry is in the same range as BCYC (33) in the null industry. This means that IOVA’s stock grew similarly to BCYC’s over the last 12 months.

IOVA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as BCYC (100) in the null industry. This means that IOVA’s stock grew similarly to BCYC’s over the last 12 months.

IOVA's SMR Rating (97) in the Biotechnology industry is in the same range as BCYC (97) in the null industry. This means that IOVA’s stock grew similarly to BCYC’s over the last 12 months.

IOVA's Price Growth Rating (34) in the Biotechnology industry is in the same range as BCYC (61) in the null industry. This means that IOVA’s stock grew similarly to BCYC’s over the last 12 months.

BCYC's P/E Growth Rating (34) in the null industry is somewhat better than the same rating for IOVA (96) in the Biotechnology industry. This means that BCYC’s stock grew somewhat faster than IOVA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCYCIOVA
RSI
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
89%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 9 days ago
80%
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
89%
Aroon
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
86%
COMPARISON
Comparison
Nov 06, 2026
Stock price -- (BCYC: $3.72 vs. IOVA: $8.70)
Brand notoriety: BCYC and IOVA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCYC: 45% vs. IOVA: 106%
Market capitalization -- BCYC: $260.37M vs. IOVA: $3.51B
BCYC [@Biotechnology] is valued at $260.37M. IOVA’s [@Biotechnology] market capitalization is $3.51B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $139.16B. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCYC’s FA Score shows that 1 FA rating(s) are green while IOVA’s FA Score has 1 green FA rating(s).

  • BCYC’s FA Score: 1 green, 4 red.
  • IOVA’s FA Score: 1 green, 4 red.
According to our system of comparison, BCYC is a better buy in the long-term than IOVA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCYC’s TA Score shows that 5 TA indicator(s) are bullish while IOVA’s TA Score has 5 bullish TA indicator(s).

  • BCYC’s TA Score: 5 bullish, 4 bearish.
  • IOVA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both BCYC and IOVA are a good buy in the short-term.

Price Growth

BCYC (@Biotechnology) experienced а -4.12% price change this week, while IOVA (@Biotechnology) price change was -41.26% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.72%. For the same industry, the average monthly price growth was -14.23%, and the average quarterly price growth was -21.13%.

Reported Earning Dates

BCYC is expected to report earnings on Mar 02, 2027.

IOVA is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-8.72% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

BCYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with PCVX. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then PCVX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCYC
1D Price
Change %
BCYC100%
+1.36%
PCVX - BCYC
57%
Loosely correlated
+8.01%
EDIT - BCYC
50%
Loosely correlated
+4.62%
RCKT - BCYC
50%
Loosely correlated
+3.98%
ARCT - BCYC
49%
Loosely correlated
+13.94%
STOK - BCYC
48%
Loosely correlated
+1.70%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IAPR33.960.64
+1.92%
Innovator International Developed Power Buffer ETF - April (IAPR)
YYY10.420.07
+0.68%
Amplify CEF High Income ETF (YYY)
JBND52.000.22
+0.42%
JPMorgan Active Bond ETF (JBND)
BBSB97.490.09
+0.09%
JPMorgan BetaBuilders U.S. Treasury Bond 1-3 Year ETF (BBSB)
EMES25.56N/A
N/A
Harbor Emerging Markets Select ETF (EMES)